# Vaxcyte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vaxcyte

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.vaxcyte.com/
- Total disclosed funding: $206M
- Latest round: Series D (Mar 20, 2020)
- Investors on record: 11

## About

Vaxcyte, Inc. is a US-based biotechnology company dedicated to developing innovative vaccines targeting bacterial infections, including invasive pneumococcal disease and Group A Streptococcus, aiming to enhance public health outcomes globally.Founded in 2013 and headquartered in San Carlos, US, Vaxcyte, Inc. specializes in vaccine development. The company, co-founded by Grant Pickering and Jeff Fairman, has shifted focus to pneumococcal conjugate vaccines, reflecting its commitment to combatting significant bacterial threats. Vaxcyte has completed a total of 10 funding deals, with the latest funding round being a Private Placement in April 2023, where the company raised USD 500.00 mn, bringing the total amount raised to USD 500.00 mn.Vaxcyte focuses on creating advanced vaccines targeting bacterial infections, particularly invasive pneumococcal disease, Group A Streptococcus, periodontitis, and Shigella. Its key offerings include the VAX-31 and VAX-24 pneumococcal conjugate vaccines, which utilize innovative synthetic techniques to effectively neutralize complex bacterial defenses. The company targets healthcare institutions and government organizations across North America, Europe, and parts of Asia.Vaxcyte's revenue generation is based on the development and commercialization of its vaccine products via strategic partnerships with healthcare providers and distributors. Revenue is expected to come from the sales of VAX-31 and VAX-24 following regulatory approval, supported by ongoing R&D to enhance its vaccine portfolio. For the year 2022, the company's EBITDA was reported as USD -224.01 mn.Looking ahead, Vaxcyte plans to utilize the USD 500.00 mn raised in its April 2023 Private Placement to advance the development of its pneumococcal vaccine candidates and bring them into clinical trials. The company is focusing on expanding its operations into new geographical markets, particularly in North America and Europe, by 2024. Vaxcyte aims to strengthen its position in the global vaccine market through strategic initiatives and partnerships.

## Funding rounds

- Series D, Mar 20, 2020, $110M — Abingworth, Frazier Healthcare Partners, TPG, CTI Life Sciences, Longitude Capital, Roche Venture Fund, Foresite Capital, RA Capital Management, Medicxi, Pivotal Life Sciences, Janus Henderson Investors
- Series C, May 29, 2018, $43M — Abingworth, Frazier Healthcare Partners, TPG, CTI Life Sciences, Longitude Capital, Roche Venture Fund, Foresite Capital, Medicxi, Pivotal Life Sciences
- Series B, Mar 3, 2017, $40M — Abingworth, Frazier Healthcare Partners, CTI Life Sciences, Longitude Capital, Roche Venture Fund, Pivotal Life Sciences
- Series A, Jul 10, 2015, $13M — Abingworth, CTI Life Sciences, Longitude Capital, Roche Venture Fund

## Investors

- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A, Series B, Series C, Series D
- CTI Life Sciences (https://capitalatlas.ai/funds/cti-life-sciences) — Series A, Series B, Series C, Series D
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A, Series B, Series C, Series D
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A, Series B, Series C, Series D
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series B, Series C, Series D
- Pivotal Life Sciences (https://capitalatlas.ai/funds/pivotal-life-sciences) — Series B, Series C, Series D
- TPG (https://capitalatlas.ai/funds/tpg) — Series C, Series D
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C, Series D
- Medicxi (https://capitalatlas.ai/funds/medicxi) — Series C, Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D
- Janus Henderson Investors — Series D